Application of clopidogrelbeforepercutaneous coronaryinterventioninpatientswith acute coronarysyndrome reducesthe risk of cardiac events. Clopidogrel administration before surgery increasesb leeding complications after CABG. Therefore, the antithromboticeffectofthe low-dose combination of clopidogreland aspirin wasinvestigatedinan in vivo pig model of coronarya rteryt hrombus formation with cyclic flowr eductions. Theplateletinhibitoryeffectwas determinedbyplateletaggregation and CFR,a ccording to the methodology describedb y Folts.CFR were initiated by endothelialdamage and placement of aconstrictor aroundthe LAD. 30 min afterCFR were established, clopidogrel (0.1 mg/kgor5mg/kg), aspirin(1mg/kg or 7 mg/kg)orLDC (0.1 mg/kg clopidogreland 1mg/kg aspirin) were administeredorally.CFR-frequencywas determinedfor further 240 min.
Introduction
Accordingtothe guidelines, percutanous coronaryintervention (PCI) is the treatment of choicei na cutec oronary syndrome (ACS). It hasbeen shown thatpatients benefitfrom an earlyinvasive approach (1, 2) . To prevent earlystent thrombosis, clopidogrel (300mg) is frequently administered before PCI is performed (3) .
Clopidogrel treatment is indicated in patients with unstable angina and non-ST-segment elevation myocardiali nfarction. It should not be used in patients whoare potentialcandidatesfor urgent coronaryarterybypass grafting (CABG) (4) .
Several studieshaveclearlydemonstrated the beneficial role of acetylsalicylic acid(ASA, Aspirin ® )inpreventing thrombotic complications in cardiovasculardiseases (5) (6) (7) (8) . Previous studies have demonstrated asynergistic effect of the combination therapywith ASA and clopidogrel under experimental and clinical conditions (9, 10) . Further trials confirmed the need for dual antiplatelett herapya fter coronarya rterys tenting (3, 11, 12) .
However, recent publications documentedthat preoperative clopidogrel therapyi sa ssociatedw ith increased mediastinal bleeding,reoperation for bleeding and transfusion requirements as well as prolonged ICUand hospital length of stay (13) (14) (15) (16) (17) (18) .
In regard to the documentedc omplications after CABG under clopidogrel pretreatment, the issue of al ow-dose combination therapyand its effect on in vivo plateletfunction is of utmost interest and suggests ad ose reduction. Therefore, it was testedinan in vivo modelofcoronary artery thrombus formation i).whetheracombination therapywith clopidogrel and ASAat dosageswhich areineffective as single therapy can still prevent coronarythrombus formation in vivo ,and ii). if in vivo observation can be confirmed by ex vivo platelet aggregation tests.
Materialand methods

Experimental model
Thirty male Landrace pigsw eighing 30 ±4kg were premedicated with the sedative azaperon intramuscularly( 7.5 mg/kg). Anesthesia wasinitiatedwith an intravenous sodium thiopental bolus (5 mg/kg) and then maintained by intravenous infusionof sodium thiopental( 10 mg/kg/h). After intubation, pigs were mechanically ventilatedw ith aD räger respirator Servo9 00b (oxygen-air:FiO 2 0.35; Pco 2 controlled) and arterial and central venous lines were introduced viat he femorala rterya nd vein (19) . For'peroral' drug administration acatheter wasplaced in the jejunumthrough asmall paramedianlaparotomy. Priortofemoral artery preparation, a7.5 mg bolus of the analgetic piritramid wasgiven intravenously and during left thoracotomypiritramid wasinfusedcontinuously (0.25 mg/kg/h).After removalof the fourthrib, the heartwas suspendedinapericardialcradleand aD oppler flowp robe( ART, Active Redirection Transit Time FlowP robe, Triton TechnologyI nc., San Diego, USA) was placed around the pulmonaryartery. ATIP-catheter wasinserted into the leftv entricular apex. Approximately 1.5 cm of the left anterior descending coronaryartery(LAD), proximal to itsfirst diagonal branch,were carefullydissected fromsurrounding tissue and apulsed ultrasonic Doppler flowprobe(Triton TechnologyInc., San Diego, USA) wasplaced aroundthe vesselfor continuous flowmeasurement.
Figure1:Scheme of the pigmodel showing anew method for producing critical coronary artery stenosis. To consider the fragility of pig coronaryarteries,intimal damage in pigs must be produced very carefully. Also, shaking theconstrictortoembolize thethrombus mayincrease the amount of intimal damageand maynot return to the samepoint on theartery, which could reduce thedegreeofstenosis. To avoidthese problems, Foltsetal. usedthe combinationofanoversized plasticoccluder andaballoon of apercutaneoustransluminal coronary angioplasty catheter,but over time thelossofpressureaffects this system adversely. Therefore, we designedanew plasticconstrictorwhich can be adjustedveryeasily and more exactly via ascaleonthe turning handle.The U-shapedlower partofthe plasticconstrictorwas placed around theleft anterior descending coronaryarteryand then connected withthe upperpart. Theupperpartwas connected to aflexible shaft, which transmitted themovementtoathread to shiftaplungertonarrowthe coronaryartery. Critical coronaryarterystenosiswas achieved by continuous reductionofthe internal diameter of theconstrictor. LAD, left anterior descending coronaryartery; VCM,venacordis magna, Ao,aorta;RCX, circumflexcoronaryartery; PA,pulmonaryartery; LA, leftatrium; CVP,centralvenouspressure.
Preparation and administration of drugs
Clopidogrel wasd issolved in non-pyrogenic aquai njectabile (SanofiRecherche, Toulouse, France) and Aspisol ® (Bayer AG, Leverkusen,Germany)was dissolved as instructedbythe manufacturer.All drugs were prepared just prior to use.Clopidogrel and ASAoracombination of these were administered viaajejunal catheter to mimic 'peroral' administration, whichc orresponds to the routine wayofadministration in humans.
Study protocol
Baselinehemodynamics, includingheartrate, systolic, diastolic and mean arterial pressure, central venous pressure (CVP), left ventricularp ressure (LVP), cardiac output and mean coronary blood flowvelocitieswere continuouslyrecorded with aSystem 6unit (Triton TechnologyInc., San Diego, USA). Cyclic flowreductions were induced as described by Folts et al.( 20, 21) by carefullys queezing the LAD distal to the pulsed ultrasonic Doppler flowprobewith asmoothed forcepstodamage the endothelium. In pigs,however,intimal damage should be performed in aw ell-controlledmanner,becauseofthe fragility of porcine coronaryarteries (22) .Therefore,wedesignedanew plastic constrictor with aflexible shaft used to reproducibly narrowthe coronarya rtery ( Fig. 1) . This special 4-mm plastic constrictor wasplaced aroundthe injured segment of the artery. Critical coronarya rterys tenosis wasa chieved by continuous reduction of the internal diameter of the constrictor,until the reactive hyperemic response to atemporary15sec occlusion wasnearlyabolished. The combination of endothelial damage and criticalstenosis resultedi ns pontaneous repetitive cyclic flow reductions whichwere monitored for atime interval of 30 min duration as baseline CFR. Thereafter,d rugo rv ehiclew ere administered ('peroral') viaaj ejunal catheter.C oronary blood flowa nd hemodynamics were thenmeasured foranother period of 240 min. Wall thickening wasm easured beforea nd after drug administration every30min until the end of the experiment. After CFR were abolished, epinephrine (0.6µg/kg/min) wasinfusedintravenouslyfor 30 min at the end of the observation time.Nosystemic heparin wasgiven at anytime during the experiment.
According to previous examinations in pigs usingc lopidogrel,westarted at adose of 5mg/kg (11, 23) . Pilot experiments with dose reduction of singleadministeredASA (7, 3and 1mg/ kg) and clopidogrel (5,3,1,and 0.1 mg/kg) led to the ineffective in vivo dosage.Thereafter, the combined application of these ineffectivelow doses wasinvestigated.
Subsequently,pigs were divided into six groups of 5animals each: group 1receivedsaline 0.9%, group 2and 3receivedASA (Group2:7mg/kg, Group 3: 1mg/kg), group 4and 5received clopidogrel (Group 4: 5mg/kg, Group 5: 0.1 mg/kg) and group 6 receivedacombination of ASA 1mg/kg and clopidogrel 0.1mg/ kg.
Forthe analysis of the antithrombotic effectsofASA,clopidogrel or the drug combination, respectively,e ach animalw as used as its owncontrol by comparing CFR prior to and post drug treatment (Fig. 2) .
All investigativeprocedures and animalfacilitiesconformed with the Guide forthe Careand Use of Laboratory Animals published by the NationalInstitutes of Health. The protocol wasapprovedbythe Institutional Animal Care and Use Committee.
Methods
Evaluationofcyclic flowreduction(CFR)
Thrombus formation at the site of injuryinthe leftanterior descending coronarya rterya nd induction of the criticals tenosis ledt ob lood flow reduction and decrease of blood velocity,r espectively. To assess the severity of CFR, the area under the blood flowvelocity curve over time is determinedbyplanimetry using ap ersonal computerb ased software system( Photoshop 6.0, AdobeS ystems Incorporated,S an Jose,U SA)a nd calculated as cm 2 /30min until cessation of CFRaccording to the publication of Just et al. (24) . Therefore, severity is zero after CFR cessation. In regard to previous publications both "severity" of cyclic flow reduction and the number of cycles per 30 min were examined (20, 21, 24) . Derivedfrom the single chartofCFR in each animal, we counted the 50% reduction of CFR to baselinein each group. Time wasmeasured when 50%reduction wasreached and dataw ere compared between groups. The existenceo f thrombus wasdocumented by explantation of the injured artery segment at the nadir of CFR in pilot experiments (Fig. 2) . Additionally, the completethrombotic occluded coronaryarterywas rapidlyexplanted in animals with evolving myocardialinfarction whereas afresh thrombotic lesion wasobserved.
Platelet aggregation studies
Bloodsamples were collected in polypropylene tubescontaining 3.8% trisodium citrate solution (9:1 v/v) before CFRand every 30 min until 240 min after 'peroral' drug administration. Platelet richplasma (PRP) wasobtained by centrifugation of the blood (300xg, 10 min, 20°C), whereas blood wasc entrifuged at 1800xg (10min, 20°C) to obtain plateletpoor plasma (PPP). Platelet aggregation wasmeasured by the turbidometric method of Bornand Cross (25) on aLABor APACTaggregometer (LABor, Ahrensburg, Germany), and PRP wase quilibrated at 37°C for 1min under constantstirring (1000 rpm).Aggregation wasinducedbyADP 3or10µM(Adenosin 5'diphosphate sodium salt, Sigma Chemie, Heidelberg) or 3or10µg/mL collagen(Collagen Reagent, Chrono-Par,Nobis LabordiagnostikGmbH,Endingen, Germany).The extent of aggregation wasestimatedb yquantitatively measuring the maximum height above baseline of the curve.
Platelet count
Before initiating CFR and at the end of the experiment, blood samples (2 mL) were collected in polypropylene tubescontaining EDTA( EDTA-Monovette ® ,B raun AG,M elsungen, Germany). 20 µL of EDTA-blood were added into aThrombo plus ® tube (Sarstedt AG,Nürnbrecht, Germany),wherehemolysis occurred immediately.The resultsw ere obtainedbyvisualcounting in amicroscopeusing aNeubauer chamber and were calculatedasplatelets/µl.
Statisticalanalyses
All data are expressed as mean±standard errorofmean. Then valuesi ndicate the number of animals studied. In aggregation studiesthe responses aree xpressed as inhibition of control aggregation. Comparisons between variableswere made usingone wayA NOVA .F or repeated measurements, ANOVA witht he multiple comparison method versusc ontrol group (Dunnett's test) wasused. Probability valuesp<0.05 were considered to indicatestatistical significance.
Results
Cyclic flowreductions
Endothelial damage of the left anterior descending coronary artery and placement of the coronaryconstrictor resulted in recurrent CFR, withmean frequencies ranging from6to10per 30 min observation interval in the variousgroups.Anexample of CFR and cessation after drug administration is giveninF igures 3A and B. Mean severity of CFR at baseline in allg roups ranged from 48 to 64 cm²/30min observation interval.Baseline and follow-up data of severity are giveninTable 2.
Afters aline administration (group1 ), the CFR continued withaslightlybut not significantly lowerfrequencyand with unaltered severity compared to the baseline period.Two pigs of this group died due to infarction 90 and 120 min, respectively,after drug administration (Table 1and Fig. 4A) .
ASA( 7m g/kg, group 2) showedat endencyf or CFRfrequencyreduction at 30 min and significantlydiminished CFR at 60 min (-48%, p<0.05vs. pretreated CFR-frequency) and at 90 min (-94%, p<0.01). An examplefor CFRcessation 60 min after ASA7 mg/kg administration is giveni nF igure3 B. CFR were abolishedafter 90 min in allpigs (Fig. 4B) .CFR reoccurred in 3 of 5animals caused by epinephrine infusions at the end of the experiment ( Table 1 ). The severity wassignificantly reduced at 90 min (-90%, p<0.01) after drug administration.
CFR-frequencyo fg roup3( ASA1 mg/kg)c ontinued unabated ranging from 6to9/30min during the 4hours of observation (Fig. 4C) .Inthis group, one of twopigs dieddue to infarction.
Followingc lopidogrel administration (5 mg/kg,g roup4 ). CFR frequencyshowedatrend to decreaseat90min. Asignificant reduction occurred at 120min (-65%, p<0.05) and at 150 min (-94%, p<0.01). In this group, CFRwere abolishedafter 180 min (Fig. 4D ). An original recording with CFR termination 80 min after drug administration is shown in Figure 3A . Epinephrine wasinfusedinfivepigs without restoring CFR (Table 1) .In this group, the severity wass ignificantly reduced 120m in (-80%, p<0.05) after drug administration.
However, the CFR-frequencycontinued unabated following clopidogrel administration at 0.1mg/kg (group 5), with its severity also not being significantlyaltered until the end of the experiment. One pig in group 5developed infarction (120min).
The combinationtherapy(group 6) of clopidogrel 0.1mg/kg and ASA 1mg/kg reducedCFR-frequencyby46% at 60 min. At Epinephrine infusion (0.6 µg/kg/min) was performedatthe endof4hours observation time after drug administration to causethe reoccurrence of CFR. Death or infarction were observedduring the experiment in three groups. Numbers presentincidences to total number of animals studied in eachgroup. 12.0±12.0* 90 min after drug administration, CFRreduction (-70%, p<0.05) wass ignificant until the end of the experiment (-70 to -80%, p<0.05). The severity of the flow reductionsw as also significantly reduced after 120min (-63%, p<0.05). However, in one pig the CFR continuedw ith onlys light reductionsb etween 30 and 120m in followingd ruga dministration. Therefore, CFR were abolishedinfour pigs (Fig. 4F) . CFRwere reintroduced in twoofthese animals after epinephrine infusion ( Table 1) . The reduction in the number of CFRb y5 0% comparedt o baseline wasaccomplishedafter 60 min in the ASA group (7 mg/ kg) and after 65 min in the combination group (clopidogrel 0.1 mg/kg +ASA 1mg/kg). This is in contrasttoclopidogrel alone, where a50% reduction wasobserved90min after drug administration (5 mg/kg,p<0.05 vs. ASA 7mg/kg and combination). The other groups (clopidogrel 0.1mg/kg,ASA 1mg/kg and control) did not showCFR reduction at all.
The stimulation of CFRunder epinephrine presents the reintroduction of plateletactivation by the adrenergicsystem. This wascompletelyabolished under 5mg/kg clopidogrel alone.
Platelet aggregation
The antiaggregating effectsofclopidogrel and ASAare shownin Figures4A-F.
ADP-induced platelet aggregation wasc learlya nd significantly inhibitedi nP RP by clopidogrel 5m g/kg (Fig. 4D ) and wasslightlyreduced by clopidogrel 0.1mg/kg (Fig. 4E) , butnot by ASA7mg/kg and 1mg/kg, respectively.Onthe other hand, collagen-induced aggregation wass ignificantly inhibitedb y ASA7m g/kg (Fig. 4B) , whereas ASA1 mg/kg (Fig. 4C) and clopidogrel had no effect.Normal saline treatment of the animals had no effect on ADP-and collagen-induced plateletaggregation (Fig. 4A) . Thecombination of lowdose clopidogrel (0.1 mg/kg) and ASA( 1mg/kg) produced no effects initiallya nd exerteda minor buts tatistically significant impacto nADP-induced aggregation after 150min without anyeffect on collagen-induced aggregation (Fig. 4F) .
Platelet count
The number of platelets as mean of all groups (n=30) was 357.000 ±20.000/µl at baseline and 350.000 ±26.000/µL at the end of the experiment, with ar angef rom 172.000/µl to 658.000/µl. No statistically significant differenceb etween groups could be observed. The decrease in plateletcount after 4 hours of cyclic flow reductionsamountedtoamaximum of 12% in individual animals.
Hemodynamicand laboratoryparameters
Mean arterial pressure, heartr ate, cardiaco utput, CVP and LV dp/dt displayed no statistically significant differences between the six groups at anytime.All laboratoryand respiratory parametersremained within physiological ranges.Therewere no statistically significant differences between groups at anytime.
Discussion
The present study demonstrates the over additive antithrombotic effect of low-doseclopidogrel and ASAinanexperimental animal model of coronaryarterythrombus formation. Our results present the in vivo antithrombotic effect occuring at clopidogrel and ASAdoses that do not inhibitoronlyslightlyreduce ex vivo platelet aggregation induced by as ingle proaggregatorym ediator.Inaddition, the onset of action in the low-dose combination group is remarkable, being already present 60-90 min following 'peroral' drug administration.
ASA is the most widelyusedantithrombotic agent in acute coronarysyndromesand chronic coronaryarterydisease (26) . It has beens hown to be highlyb eneficiali nt he treatment of unstable angina (8, 27 ). However, ASAfails to be preventiveina certain number of patients, whichmay be partlydue to the fact thatASA inhibits just oneo ft he several existing plateleta ctivation pathways (8) . The different and complementaryADP-dependent platelet activation and amplifying pathwaysare irreversibly inhibitedbyclopidogrel whichwas previously published for CFRi nhibition in femorala rteries (23) .A fter oral administration, clopidogrel is absorbed fromt he gastrointestinal tract and rapidlymetabolized in the liver. Therefore,the antiaggregatoryeffect of clopidogrel in humans is detectable ex vivo within 2to4hours after administration of the loading dose (300 mg).
Underour experimental conditions, plateletaggregation data present asignificant reduction at ASA7mg/kg and with clopidogrel 5mg/kg.Inhibition of plateletaggregation at 0.1mg/kg was attenuatedand none wasfound at ASA 1mg/kg. However, in the low-dosec ombination group inhibition of plateleta ggregation wassignificantly reduced butclose to the group with administration of 0.1 mg/kg clopidogrel.
In contrastt ot he data of ex vivo plateleta ggregation, inhibitionof in vivo CFR wasmuch more pronounced at low-dose combination of ASA and clopidogrel versuse itherc ompound alone.However,CFR could not be completelyabolished in one animal and were reintroduced by epinephrine infusions in 2of4 animals butalso in 3of5animals at ASA 7mg/kg. This observation mayi ndicate that other stimuli,i .e. changes in hemodynamics, activation of the adrenergicsystem or an increase in stenosis severity causing an increase in shear stress, mayovercome the anti-thrombotic action of ASA (28, 29) . CFRw ere reintroducedi n3o f5p igs at ASA7m g/kg. The underlying mechanisms have beenshown in previous studies (30) (31) (32) (33) .
These experimental findings ares upported by previously published examinations in astent modelof in vivo arterial thrombosis in pigs.I nt hese experiments clopidogrel plus ASA changed the thrombus structurea nd destabilizedt he thrombus without complete abolishment of plateletreactivity (34) . Additionally, in regard to the in vivo processo fa rterial thrombosis caused by avesselwallinjuryleading to subendothelialmatrix exposure and endothelial mediator release, the in vitro initiation of plateleta ggregation is achieved by supraphysiological concentration of asingle inductor.Begent and Borndemonstrated in vivo that10to180 x10 -14 mol ADP aresufficient to induce aplatelett hrombus (35) .I nc omparison to these physiological concentrations,itseemsobvious thataneffectiveinhibition just sufficient to eliminate plateletthrombus formations in vivo is overcomeb ysupraphysiological inductor concentrations in vitro (3 and 10 µM ADP). Thus,the use of asingle mediator for platelet aggregation in vitro or ex vivo testing appliedinhigherconcentrations seems to be of limited value to predict in vivo anti-thrombotic efficacy(inhibition of CFR) within coronaryarteries.
The present findings go along with several previousstudies demonstrating that the combination of ASA and clopidogrel in vivo and ex vivo is superior in preventing stent thrombosis as compared to therapywithASA alone (12, 22) . Furthermore,Herbertetal. showedthat ASA potentiates the antithromboticactivity of clopidogrel in rabbits (9) . In addition, ac ombination of high dose clopidogrel,ketanserinand thromboxane synthase inhibitor ridogrel reduced CFR and neointimalproliferation under coronaryflowvariations after angioplasty in dogs (36) . Similar to our findings, clopidogrel treatment alonei nd ogsp revented CFRathigh dosage (37) .
In contrasttothese high dose regimen studies, thereare no publishedc linical or experimental data investigating the antithrombotic effect of alow-dose combination of ASA and clopidogrel as presented in this study.
Previous publications concerning coronarya rteryb ypass grafting under combination of clopidogrel plus ASAreported increased postoperative bleeding,b lood product transfusions, reoperations forb leeding and morbiditiy (13) (14) (15) (16) (17) (18) . These findings raise the concernregarding routine treatment of combined high dosage ASA and clopidogrel beforedefinite coronarystent implantation, resulting in the recommendation not to administer these drugs in patients whoa re potentialc andidatesf or urgent CABG (4) .Onthe other hand,the resultsofthe Clopidogrel for the Reduction of Eventsd uring Observation (CREDO) trial pointed to ab ettero utcome for clopidogrel plus ASAv ersus ASAand placebo when givensix or morehours prior to percutaneous intervention (3).T herefore,f urther experimental and clinicaltrials for dose response relationship of pharmacological platelet inhibition with clopidogrel and ASAb efore CABG should be performed.
In conclusion,inthis animal model of coronarythrombosis due to platelet-inducedthrombus formation, ineffective dosages of clopidogrel and ASAalone turnedout to be potent in combination. The in vivo effect wasnot mirrored by the ex vivo platelet aggregation.
Limitations
Formeasurement of the anti-aggregant effect of ASA and clopidogrel,c ollagen and ADP dependent plateleta ctivation was used. According to our data,weobservedthe timedependentinhibition of in vitro plateletaggregation. Indeed,one study limitation could be the unknown metabolism of clopidogrel and its activem etabolite in pigs.I nr egard to previous publications in pig models, noneofthe authorsmeasured the pharmacokinetics of clopidogrel.Concerning clopidogrel plasma concentrations in pigs,n eitherS anofi Research norB ristol Meyers Squibbh ave performed anym easurements( personal communications J.M. Herbert, Sanofi-Aventis, Toulouse).
